Breaking News, Collaborations & Alliances

Forest, Nabriva In Development Pact

Forest to fund development of antibacterial agent

Forest Laboratories, Inc. and Nabriva Therapeutics have entered into an agreement for the development of Nabriva’s antibacterial agent, BC-3781. Forest will provide $25 million and fund and conduct in collaboration with Nabriva, certain development activities related to BC-3781 for the next 12 months, during which Forest has the exclusive right to acquire Nabriva. The transaction is subject to customary regulatory clearances.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters